Antibodies as Drugs: Engineering Next-Generation Therapeutics (B1)
February 7-10, 2028
| La Fonda on the Plaza, Santa Fe, NM, United States
Christian Klein, Janine Schuurman and Mark S Cragg
| 4:00–8:00 PM |
Registration |
|
| 6:00–8:00 PM |
Welcome Mixer |
|
Tuesday, February 8, 2028
| 8:00–8:30 AM |
Poster Setup |
|
| 8:15–5:00 PM |
Poster Viewing |
|
| 8:30–8:40 AM |
Welcome Remarks |
|
| 8:40–9:30 AM |
Keynote Address |
|
| |
James A Wells †, University of California, San Francisco
Antibody-based Degraders |
|
| 9:30–11:45 AM |
Next Generation T Cell Engagers |
|
| |
Christian Klein, Biotech Startup
Progress with T Cell Engagement |
|
| |
Geetha Shankar †, Vir Biotechnology, Inc.
Progress with Tumor-Activated T Cell Engagers |
|
| |
Burcu Yigit †, Cartography Biosciences
Multispecific T Cell Engagers |
|
| |
Short Talk(s) Chosen from Abstracts
|
|
| 10:00–10:20 AM |
Coffee Break |
|
| 2:30–4:30 PM |
Symposia Spotlight 1: Therapeutic Antibodies for Oncology, I&I, Metabolism, CNS, and Infection |
|
| |
* Christian Klein, Biotech Startup
|
|
| |
* Janine Schuurman, Lust for Life Science
|
|
| |
Short Talks Chosen from Abstracts
|
|
| 4:30–5:00 PM |
Coffee Available |
|
| 5:00–7:00 PM |
Computational Design and Lab-in-the-Loop Engineering of Biologics |
|
| |
Charlotte Deane †, University of Oxford
In silico Design of CDRs |
|
| |
Sarel J. Fleishman †, Weizmann Institute of Science
Energy-Guided Combinatorial Co-Optimization of Antibody Affinity and Stability |
|
| |
Peyton Greenside †, BigHat Biosciences
Antibody Learning Loop: Prediction and Experimental Validation/Optimization |
|
| |
Short Talk(s) Chosen from Abstracts
|
|
| 7:00–8:00 PM |
On Own for Dinner |
|
Wednesday, February 9, 2028
| 8:00–8:30 AM |
Poster Setup |
|
| 8:15–5:00 PM |
Poster Viewing |
|
| 8:30–11:30 AM |
Mechanisms of Action |
|
| |
Janine Schuurman, Lust for Life Science
Overview on Novel MOAs for Antibody-based Therapies |
|
| |
Pamela M. Holland †, InduPro
Making use of Proximity for Novel cis-Targeted Antibody MOAs |
|
| |
Stefan Zielonka †, Clemens-Schöpf-Institut, Technische Universität Darmstadt
VHH-based Antibody Mimetics |
|
| |
Rony Dahan †, Weizmann Institute of Science
Bi- and Tri-specific Antibodies Linking Innate and Adaptive Immunity |
|
| |
Short Talk(s) Chosen from Abstracts
|
|
| 9:30–9:50 AM |
Coffee Break |
|
| 3:00–4:30 PM |
Career Roundtable |
|
| 4:30–5:00 PM |
Coffee Available |
|
| 5:00–7:00 PM |
Antibody Drug Conjugates and Radioimmunotherapy |
|
| |
Raffaele Colombo †, Zymeworks Inc.
The Evolution of Antibody Drug Conjugates |
|
| |
Andrew Souers †, AbbVie
Degrader Antibody Conjugates Targeting Bcl Family Members |
|
| |
Sofia Frost †, Roche
Novel Split Pre-Targeted Radioimmunotherapy |
|
| |
Short Talk(s) Chosen from Abstracts
|
|
| 7:00–8:00 PM |
On Own for Dinner |
|
Thursday, February 10, 2028
| 8:30–11:30 AM |
Approaches for Autoimmunity, Infectious Diseases, and CNS Diseases |
|
| |
Joy Yu Zuchero †, Denali Therapeutics Inc
Delivering Antibodies Over the Blood Brain Barrier for CNS Diseases |
|
| |
Robert A. Seder †, NIAID, National Institutes of Health
Developing Long-Acting Antibodies for Malaria |
|
| |
Chris Paluch †, Gilead Sciences
Antibody Agonists for AID |
|
| |
Lucy Dorrell †, Immunocore
Targeting HIV Gag77-85 for Eradication with a Bispecific TCR ImmTac |
|
| |
Short Talk(s) Chosen from Abstracts
|
|
| 9:30–9:50 AM |
Coffee Break |
|
| 11:40–12:40 PM |
Panel Discussion: Where are Next Generation Antibodies and Design Heading? |
|
| 2:30–4:30 PM |
Symposia Spotlight 2: AI/ML in Antibody Engineering |
|
| |
* Mark S Cragg, University of Southampton
|
|
| |
Short Talks Chosen from Abstracts
|
|
| 4:30–5:00 PM |
Coffee Available |
|
| 5:00–6:45 PM |
Therapeutic Innovation with Engineered Antibodies |
|
| |
Ricardo Grieshaber-Bouyer †, Friedrich-Alexander-Universität Erlangen-Nürnberg and Universitätsklinikum Erlangen
TCEs and CAR-T Cells for B and Plasma Cell Depletion in Autoimmune Patients |
|
| |
Mark S Cragg, University of Southampton
Engineering Antibodies for Receptor Agonism |
|
| |
Susan M. Galbraith †, AstraZeneca
Clinical Progress with Antibody Drug Conjugates |
|
| |
Short Talk(s) Chosen from Abstracts
|
|
| 6:45–7:00 PM |
Meeting Wrap-Up: Outcomes and Future Directions |
|
| 7:00–8:00 PM |
On Own for Dinner |
|
Friday, February 11, 2028
